These include pembrolizumab and dostarlimab for microsatellite instability-high or TMB-high tumors [46,47], BRAF/MEK inhibitors dabrafenib plus trametinib for BRAF V600E mutant tumors, the RET inhibitor selpercatinib for cancers with RET fusions [48], and NTRK tyrosine kinase inhibitors (TKIs) such as entrectinib and larotrectinib for NTRK fusions [49]. This evidence concerns the gene MAP2K7 and cancer.